Results 221 to 230 of about 84,228 (303)

Pancreatic Ductal Adenocarcinoma

, 2012
Eric P. Tamm, Jason B. Fleming, Gauri R. Varadhachary   +2 more
openaire   +2 more sources

Expression of Claudin-18.2 in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. [PDF]

Front Med (Lausanne)
Al Subhi M, Al-Nabhani D, Al Sarmi M, Abd Elrahman A, AlSawafi Y, Sirasanagandla SR, Al-Mufargi Y.   +6 more
europepmc   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Spatial heterogeneity of antibody-drug conjugate targets in pancreatic ductal adenocarcinoma. [PDF]

J Pathol Clin Res
Sabtan D, Eich ML, Loch F, Pérez Zuschneid JK, Möbs M, Böhme J, Klauschen F, Horst D, Dragomir MP, Dernbach G, Schallenberg S.   +10 more
europepmc   +1 more source

miRNA Profiling of Cholesteatoma‐Derived Exosomes Reveals Exosomal miR‐223‐3p and miR‐142‐5p as Potential Biomarkers for Acquired Middle Ear Cholesteatoma

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objectives Acquired cholesteatoma is an abnormal and invasive growth of keratinized squamous epithelial cells in the middle ear. The study aims to explore the role of exosomal miRNAs in the pathogenesis of acquired cholesteatoma and their potential in clinical application.
Qi Tang, Meng‐Yao Xie, Shu Wang, Zhi‐Yuan Wu, Zhi‐Jin Han, Chen Li, Shu‐Yi Wang, Yuan Cao, Yu‐Run Chen, Bin Wang, Ying‐Ying Shang, Xiao‐Wu Huang, Hua Yang   +12 more
wiley   +1 more source

Tumor-Infiltrating Natural Killer Cell Characterization in Pancreatic Ductal Adenocarcinoma. [PDF]

Cells
Maia A, Calá H, de Sousa E, Lérias JR, Gorgulho CM, António PA, Kamiki J, Ligeiro D, Borrego LM, Maeurer M, Castillo-Martin M.   +10 more
europepmc   +1 more source

Fingerprinting the Metabolic and Lipidomic Landscapes of Pancreatic Ductal Adenocarcinoma with MALDI Imaging. [PDF]

Clin Cancer Res
Yousf S, Glunde K, Brown DR, Tressler C, Solaiyappan M, Krishnamachary B, Mironchik Y, Dbouk M, Goggins MG, Bhujwalla ZM.   +9 more
europepmc   +1 more source

Radiological Findings Post Autologous Fat Grafting and Breasts Procedures: Avoiding False Positive Results

ANZ Journal of Surgery, EarlyView.
This article highlights the importance of understanding the imaging features and complications of fat necrosis and oil cysts to improve diagnostic accuracy and clinical management. A rational diagnostic sequence—emphasizing comparison with prior imaging, careful evaluation of morphological changes, and judicious use of biopsy—can reduce unnecessary ...
Eduardo de Faria Castro Fleury
wiley   +1 more source

Construction of an efferocytosis related signature to predict the prognosis of pancreatic ductal adenocarcinoma. [PDF]

Discov Oncol
Li J, Du Z, Liu X, Pan T, Zheng Y, He Y.
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source